Embedded Files
PIK3CA Testing now available at The Medical City - Ortigas
What is PIK3CA?
What is PIK3CA?
The PIK3CA gene encodes the p110-alpha protein which is a catalytic subunit of the class I PI 3-kinases (PI3K). Class I PI3K are heterodimeric molecules composed of a catalytic subunit, a p110, and a regulatory subunit. PI3K is frequently altered in cancer through gain-of-function mutations in two “hotspot” regions of PIK3CA exons 9 and 20. PIK3CA mutations lead to constitutive activation of p110-alpha enzymatic activity, stimulate AKT signaling, and allow growth factor-independent growth. In addition, when expressed in normal cells, these mutations allow anchorage-independent growth, further attesting to their important role in cancer development.
The PIK3CA gene encodes the p110-alpha protein which is a catalytic subunit of the class I PI 3-kinases (PI3K). Class I PI3K are heterodimeric molecules composed of a catalytic subunit, a p110, and a regulatory subunit. PI3K is frequently altered in cancer through gain-of-function mutations in two “hotspot” regions of PIK3CA exons 9 and 20. PIK3CA mutations lead to constitutive activation of p110-alpha enzymatic activity, stimulate AKT signaling, and allow growth factor-independent growth. In addition, when expressed in normal cells, these mutations allow anchorage-independent growth, further attesting to their important role in cancer development.
Why is it important to test for PIK3CA mutation in breast cancer?
PI3K/AKT/mTOR is activated in approximately >70% of breast cancers leading to tumor growth & progression, and resistance to anticancer therapies.
Approximately 40% of patients with ER+, HER2– tumors have PIK3CA gene mutations.
PIK3CA mutations are indicative of poor prognosis and worse disease outcome
When should PIK3CA Testing be done?
Biopsy is encouraged at first metastasis, and when feasible, at the time of disease recurrence to test for biomarkers that guide therapy for metastatic disease. PIK3CA mutations may be studied in metastatic tumor tissue or in archival primary tumor.
What are the requirements for PIK3CA Testing?
PIK3CA Testing Request Forms
Click the forms below to download the files via Google Drive.
TMC-PATIENT'S COPY PIK3CA Testing Request FORM 052821.pdfTMC-THIRD PARTY'S COPY PIK3CA Testing Request FORM 052821.pdfTMC-LABORATORY'S COPY PIK3CA Testing Request FORM 052821.pdfNovartis shall subsidize approximately 41% of the total PIK3CA test cost excluding the transport/handling fees.
Novartis shall subsidize approximately 41% of the total PIK3CA test cost excluding the transport/handling fees.
What is the process for PIK3CA Testing?
For inquiries, please contact
For inquiries, please contact
Landline: (+632) 8988-1000 ext. 3175/6415
Mobile: 0961-8586606
Email: moleculardx@themedicalcity.com
References
http://atlasgeneticsoncology.org/Genes/PIK3CAID415ch3q26.html;
Samuels Y, et al. Science 2004;304:554;
Bader AG, et al. Proc Natl Acad Sci USA, 2006 Jan 31;103(5):1475-9;
Kang S, et al. Proc Natl Acad Sci USA. 2005 Jan 18;102(3):802-7. Epub 2005 Jan 12.;
Liu P, et al. Nat Rev Drug Discov 2009;8:627–644;
Saal LH, et al. Proc Natl Acad Sci USA 2007;104:7564–7569;
Huang W-C, Hung M-C. J Formos Med Assoc 2009;108:180–194;
Miller TW, et al. Breast Cancer Res 2011;13:224.
Cancer Genome Atlas Network. Nature 2012;490:61-70.
Li SY, et al. Breast Cancer Res Treat. 2006;96:91-95;
Mosele F, et al. AACR 2019. Abstract 4895 [poster].
Rugo HS, et al. J Clin Oncol. 2016;34(25):3069-3103;
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer V6.2020;
Cardoso F, et al. Ann Oncol. 2020;S0923- 7534(20)42460-3.
Page updated
Google Sites
Report abuse